These results indicate that chemerin treatment blocks the increase in the RANKL/OPG ratio in osteoblastic cells stimulated with conditioned medium from MDA-MB-231 breast cancer cells, thereby preventing RANKL-induced osteoclastogenesis and breast cancer cell-associated bone loss. The gene discussed is TNFRSF11B; the disease is breast cancer.